Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyTransplantationDiseaseMalignant MeningitisNHL, B-Cell Type, Diffuse Large CellNHL, B-cell type, primary Lymphoma of the central nervous system SubgroupICD10C79.3C83.3MeSHCentral Nervous System NeoplasmsMeningeal CarcinomatosisSequenceFreiburg CNS-NHL StudyMARTA: RITU375/MTRX3500/CYTA2000, NHL, CNS-NHL, Ind. (PID2965) -|- MARTA - RITU375/BSLF3,2/THTP5, Cons. (PID2966)MTRX8000/RITU375/TMZL150, CNS lymphoma, C1 (PID1859) -|- C2 (PID1860) -|- C3 (PID1861) -|- C4 (PID1864) -|- C5 (PID1865) -|- C6 (PID1866)RITU375/MTRX3500/PRCR100/VNCR2, CNS lymphoma, C1-3 (PID1896) -|- RITU375/CYTA3000, C4-6 (PID1901)ChemotherapyChemo-substanceBusulfanCarmustineCytarabineIfosfamideMethotrexateProcarbazineRituximabTemozolomideThiotepaVincristineChemo-substanceBusulfanCarmustineCytarabineIfosfamideMethotrexateProcarbazineRituximabTemozolomideThiotepaVincristineChemo-substanceBusulfanCarmustineCytarabineIfosfamideMethotrexateProcarbazineRituximabTemozolomideThiotepaVincristineChemo-substanceBusulfanCarmustineCytarabineIfosfamideMethotrexateProcarbazineRituximabTemozolomideThiotepaVincristineNo. Substances1234 RadiotherapySupportive therapySupportive substanceAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLevetiracetamMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateNo. Substances389111213141516Protocol classificationTherapy classificationalternativecurrent standardIntensityhigh doseStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseautologous stem cell transplantationConsolidationInductionTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHepatotoxicityHyperbilirubinemiaHyperglycemiaHyperkalemiaHypokalemiaHyponatremiaIncrease AminotransferasesInfectionsLeukopeniaLymphopeniaMucositisNephrotoxicityNeutropeniaPneumonitisPyrexiaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorBirnbaum THouillier CIllerhaus GRubenstein JRubenstein JLSchorb EDiseaseErstdiagnose eines primären NHL des ZNS, 18-65 Jahreneudiagnostiziertes primäres ZNS-Lymphom, > 60 JahreNeudiagnostiziertes primäres ZNS-Lymphom, > 65 Jahre, ECOG 0-2Neudiagnostiziertes primäres ZNS-Lymphom, ECOG 0-2Primäres ZNS-LymphomWiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50OriginAlbert-Ludwigs University, Freiburg, Germany, Freiburger ZNS-NHL ProtokollDepartment of Neurology, Ludwig-Maximilians-University, Munich, GermanyDivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkHelen Diller Comprehensive Cancer Center, University of California, San Francisco, CALGB 50202 (Alliance 50202)Universites Paris, Paris, France, LOC network studyUniversity of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, MARTA trialProtocols in Revision 16 protocols foundMARTA - Rituximab 375 / Busulfan 3.2 / Thiotepa 5, primary central nervous system Lymphoma, consolidation therapy (PID2966 V1.0)MARTA - Rituximab 375 / Methotrexate 3500 / Cytarabine 2000, primary central nervous system Lymphoma, induction (PID2965 V1.0)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, primary central nervous system Lymphoma, Cycle 1 (PID1859 V1.1)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, primary central nervous system Lymphoma, Cycle 2 (PID1860 V1.3)Methotrexate 8000 / Temozolomide 150, primary central nervous system Lymphoma, Cycle 3 (PID1861 V1.3)Methotrexate 8000 / Temozolomide 150, primary central nervous system Lymphoma, cycle 4 (PID1864 V1.3)Methotrexate 8000 / Temozolomide 150, primary central nervous system Lymphoma, cycle 5 (PID1865 V1.3)Rituximab 25, Malignant Meningitis (PID2571 V1.0)Rituximab 375 / Carmustine 400 / Thiotepa 5, primary central nervous system Lymphoma, conditioning, cycle 5 (PID1883 V1.0)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, primary central nervous system Lymphoma, induction, cycle 3 (PID1881 V1.0)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, primary central nervous system Lymphoma, induction, cycle 4 (PID1882 V1.0)Rituximab 375 / Cytarabine 3000, primary central nervous system Lymphoma, cycles 4?6 (PID1901 V1.1)Rituximab 375 / Methotrexate 3500 / Procarbazine 100 / Vincristine 2, primary central nervous system Lymphoma, cycles 1-3 (PID1896 V1.3)Rituximab 375 / Methotrexate 4000 / Ifosfamide 1.5, primary lymphoma of the central nervous system (PID3216 V1.0)Rituximab 375 / Methotrexate 8000, primary central nervous system Lymphoma, induction, cycle 1 (PID1879 V1.2)Rituximab 375 / Methotrexate 8000, primary central nervous system Lymphoma, induction, cycle 2 (PID1880 V1.2)
